CHARMACY PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.8 HKD | -1.00% |
|
+39.82% | +6.48% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 836.6 | 768.1 | 718.1 | 494.5 | 491 | 657.2 |
| Enterprise Value (EV) 1 | 1,730 | 1,754 | 1,305 | 1,147 | 1,176 | 1,339 |
| P/E ratio | 18.7 x | 16.9 x | 17.9 x | 12.2 x | 21.2 x | 7.27 x |
| Yield | 3.87% | 4.22% | 3.01% | 4.37% | - | 7.4% |
| Capitalization / Revenue | 0.2 x | 0.2 x | 0.21 x | 0.12 x | 0.13 x | 0.16 x |
| EV / Revenue | 0.42 x | 0.45 x | 0.37 x | 0.29 x | 0.31 x | 0.32 x |
| EV / EBITDA | 18 x | 15.2 x | 12.6 x | 11.1 x | 11.6 x | 11.2 x |
| EV / FCF | -3.39 x | -14.9 x | 15.2 x | -74.6 x | -41.4 x | -9.18 x |
| FCF Yield | -29.5% | -6.73% | 6.57% | -1.34% | -2.41% | -10.9% |
| Price to Book | 1.83 x | 1.61 x | 1.48 x | 0.98 x | 0.97 x | 1.11 x |
| Nbr of stocks (in thousands) | 108,000 | 108,000 | 108,000 | 108,000 | 108,000 | 108,000 |
| Reference price 2 | 7.746 | 7.112 | 6.649 | 4.579 | 4.547 | 6.085 |
| Announcement Date | 4/11/18 | 4/18/19 | 4/22/20 | 4/27/21 | 4/28/22 | 4/28/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4,096 | 3,935 | 3,493 | 3,992 | 3,794 | 4,175 |
| EBITDA 1 | 95.97 | 115.2 | 103.9 | 103.4 | 101.1 | 119.2 |
| EBIT 1 | 83.25 | 98.62 | 84.74 | 83.52 | 73.9 | 93.49 |
| Operating Margin | 2.03% | 2.51% | 2.43% | 2.09% | 1.95% | 2.24% |
| Earnings before Tax (EBT) 1 | 59.86 | 63.66 | 55.04 | 54.74 | 32.98 | 122.1 |
| Net income 1 | 44.76 | 45.43 | 40.15 | 40.56 | 23.15 | 90.38 |
| Net margin | 1.09% | 1.15% | 1.15% | 1.02% | 0.61% | 2.16% |
| EPS 2 | 0.4144 | 0.4207 | 0.3718 | 0.3755 | 0.2144 | 0.8369 |
| Free Cash Flow 1 | -509.8 | -118 | 85.69 | -15.38 | -28.39 | -145.9 |
| FCF margin | -12.45% | -3% | 2.45% | -0.39% | -0.75% | -3.49% |
| FCF Conversion (EBITDA) | - | - | 82.48% | - | - | - |
| FCF Conversion (Net income) | - | - | 213.41% | - | - | - |
| Dividend per Share 2 | 0.3000 | 0.3000 | 0.2000 | 0.2000 | - | 0.4500 |
| Announcement Date | 4/11/18 | 4/18/19 | 4/22/20 | 4/27/21 | 4/28/22 | 4/28/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 894 | 985 | 587 | 652 | 685 | 682 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 9.313 x | 8.554 x | 5.651 x | 6.31 x | 6.78 x | 5.72 x |
| Free Cash Flow 1 | -510 | -118 | 85.7 | -15.4 | -28.4 | -146 |
| ROE (net income / shareholders' equity) | 9.78% | 9.52% | 8.36% | 8.23% | 4.6% | 16.5% |
| ROA (Net income/ Total Assets) | 2.27% | 2.55% | 2.18% | 1.97% | 1.66% | 2.08% |
| Assets 1 | 1,971 | 1,779 | 1,841 | 2,060 | 1,394 | 4,354 |
| Book Value Per Share 2 | 4.220 | 4.410 | 4.480 | 4.650 | 4.670 | 5.500 |
| Cash Flow per Share 2 | 0.7000 | 0.5200 | 4.690 | 5.470 | 5.830 | 4.560 |
| Capex 1 | 126 | 97.7 | 73.9 | 52 | 25 | 8.59 |
| Capex / Sales | 3.07% | 2.48% | 2.12% | 1.3% | 0.66% | 0.21% |
| Announcement Date | 4/11/18 | 4/18/19 | 4/22/20 | 4/27/21 | 4/28/22 | 4/28/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +6.48% | 192M | |
| -29.67% | 10.84B | |
| -28.54% | 6.06B | |
| +8.14% | 6.04B | |
| -11.41% | 5.86B | |
| -1.17% | 4.69B | |
| +52.19% | 4.29B | |
| -12.31% | 3.61B | |
| -14.86% | 3.33B | |
| -6.93% | 3.01B |
- Stock Market
- Equities
- 2289 Stock
- Financials Charmacy Pharmaceutical Co., Ltd.
